# reload+after+2024-01-22 16:46:34.334854
address1§25B Vreeland Road
address2§Suite 300
city§Florham Park
state§NJ
zip§07932
country§United States
phone§800 208 3343
website§https://www.pdsbiotech.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies. The company is developing various product candidates, which are in preclinical trials, including PDS0102 T-cell receptor gamma alternate reading frame protein (TARP) for treating prostate and breast cancers; PDS0103 (MUC-1) for ovarian, colorectal, lung, and breast cancers; and PDS0104, which include Tyrosinase-related protein 2 for the treatment of melanoma. In addition, it is developing PDS0201 for treating tuberculosis; PDS0202, an influenza vaccine candidate; and PDS0203, a vaccine for the prevention of COVID-19. The company has a license and collaboration agreements with National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH. PDS Biotechnology Corporation was founded in 2005 and is based in Florham Park, New Jersey.
fullTimeEmployees§26
companyOfficers§[{'maxAge': 1, 'name': 'Dr. Frank K. Bedu-Addo Ph.D.', 'age': 58, 'title': 'President, CEO & Director', 'yearBorn': 1965, 'fiscalYear': 2022, 'totalPay': 854100, 'exercisedValue': 0, 'unexercisedValue': 6327625}, {'maxAge': 1, 'name': 'Ms. Lauren V. Wood M.D.', 'age': 63, 'title': 'Chief Medical Officer', 'yearBorn': 1960, 'fiscalYear': 2022, 'totalPay': 568500, 'exercisedValue': 0, 'unexercisedValue': 1763974}, {'maxAge': 1, 'name': 'Mr. Lars Robert Boesgaard M.B.A.', 'age': 53, 'title': 'Chief Financial Officer', 'yearBorn': 1970, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Joe J. Dervan', 'title': 'VP of Research & Development', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Gregory L. Conn Ph.D.', 'age': 68, 'title': 'Chief Scientific Officer', 'yearBorn': 1955, 'fiscalYear': 2022, 'totalPay': 220463, 'exercisedValue': 0, 'unexercisedValue': 325366}, {'maxAge': 1, 'name': 'Ms. Deanne  Randolph', 'title': 'Head of Investor Relations', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Spencer  Brown J.D.', 'age': 53, 'title': 'Senior VP & General Counsel', 'yearBorn': 1970, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Sanjay  Zaveri', 'title': 'Senior Vice President of Business Development', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Janetta  Trochimiuk', 'age': 60, 'title': 'Controller', 'yearBorn': 1963, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§7
boardRisk§7
compensationRisk§8
shareHolderRightsRisk§8
overallRisk§7
governanceEpochDate§1704067200
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§2
payoutRatio§0.0
beta§1.697
currency§USD
dateShortInterest§1702598400
forwardEps§-1.71
pegRatio§-0.04
exchange§NCM
quoteType§EQUITY
shortName§PDS Biotechnology Corporation
longName§PDS Biotechnology Corporation
firstTradeDateEpochUtc§1443619800
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§2f540eb1-cdf5-3fd8-b6a8-04ba9eee777b
gmtOffSetMilliseconds§-18000000
targetHighPrice§21.0
targetLowPrice§14.0
targetMeanPrice§17.67
targetMedianPrice§17.5
recommendationMean§1.9
recommendationKey§buy
numberOfAnalystOpinions§6
quickRatio§5.927
grossMargins§0.0
ebitdaMargins§0.0
trailingPegRatio§None
